Pierwotna nadczynność przytarczyc w ciąży — wyzwanie diagnostyczne i terapeutyczne by Rutkowska, Joanna et al.
270
Opis przypadku/Case repOrt
Endokrynologia Polska
DOI: 10.5603/EP.2015.0034
Tom/Volume 66; Numer/Number 3/2015
ISSN 0423–104X
Joanna Rutkowska M.D., Clinic of Endocrinology, Diabetology, and Internal Medicine, University of Varmia and Masuria,  
Żołnierska St. 18, 10–561 Olsztyn, Poland, tel.: +48 605 602 160, e-mail: rutkowskaj@wp.pl
Primary hyperparathyroidism in pregnancy  
— a diagnostic and therapeutic challenge
Pierwotna nadczynność przytarczyc w ciąży  
— wyzwanie diagnostyczne i terapeutyczne
Joanna Rutkowska1, Elżbieta Bandurska-Stankiewicz1, Wojciech Matuszewski1,  
Marek Gowkielewicz2, Radosław Goraj3, Dariusz Onichimowski3
1Clinic of Endocrinology, Diabetology, and Internal Medicine, University of Varmia and Masuria, Olsztyn, Poland 
2Department of Gynaecology and Obstetrics, General District Hospital, Olsztyn, Poland 
3Department of Anaesthesiology and Intensive Care Medicine, University of Varmia and Masuria, Olsztyn, Poland
Abstract
Hypercalcaemia during pregnancy is uncommon, and mostly associated with primary hyperparathyroidism (pHPT). If unrecognised, it 
poses a significant risk for the mother and the foetus. Maternal symptoms include: hyperemesis, muscle weakness, pancreatitis, nephrolithi-
asis, bone disease, mental status changes, and hypercalcaemic crisis. Untreated disease complicates foetal development and foetal death 
is a significant risk. Our case illustrates the difficulty in detecting pHPT during pregnancy, serious complications connected with severe 
hypercalcaemia, and difficulties in preparing the patient for surgical treatment. Our review of the medical literature did not identify any 
previous case of a pregnant woman with hypercalcaemic crisis (total calcium 17 mg/dL, parathyroid hormone 2302 pg/mL), acute pancreatitis 
caused by pHPT, and with hyperthyroidism, who had undergone a successful surgical treatment. (Endokrynol Pol 2015; 66 (3):  270–274)
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Streszczenie
Hyperkalcemia w ciąży jest rzadko spotykanym zaburzeniem. Jej główną przyczyną jest pierwotna nadczynność przytarczyc (pHPT). 
Brak prawidłowo postawionego rozpoznania stanowi ryzyko zarówno dla matki, jaki płodu. Wśród objawów występujących u matki 
wymienia się wymioty, osłabienie siły mięśniowej, ostre zapalenie trzustki, kamicę nerkową, objawy kostne, zaburzenia psychiczne 
i przełom hiperkalcemiczny. Nieleczona hiperkalcemia może być przyczyną ograniczenia wzrostu, a także obumarcia płodu. Przedstawiony 
przypadek ukazuje trudności w rozpoznaniu pHPT w ciąży, poważne powikłania ciężkiej hiperkalcemii oraz trudności w przygotowaniu 
pacjentki do leczenia operacyjnego. W dotychczas opublikowanej literaturze według wiedzy autorów pracy nie przedstawiano przypadku 
ciężarnej z przełomem hiperkalcemicznym (całkowite stężenie wapnia 17 mg/dl, parathormon 2302 pg/ml), ostrym zapaleniem trzustki 
z towarzyszącą nadczynnością tarczycy, u której przeprowadzono skuteczne leczenie operacyjne. (Endokrynol Pol 2015; 66 (3):  270–274)
Słowa kluczowe: pierwotna nadczynność przytarczyc; przełom hiperkalcemiczny; ciąża; ostre zapalenie trzustki
Introduction
Primary hyperparathyroidism results from the exces-
sive secretion of parathyroid hormone (PTH) and is 
caused by a single parathyroid adenoma. The disorder 
is common and usually asymptomatic. Primary hyper-
parathyroidism (pHPT) is uncommon in pregnancy and 
often goes undiagnosed due to gestational physiologi-
cal changes. The majority of women with pHPT have 
a history of one or more miscarriages. Worsening of 
hypercalcaemia may cause a hypercalcaemic crisis dur-
ing pregnancy or after delivery [1, 2]. Untreated disease 
complicates foetal development, and foetal death is 
a significant risk. The recommended treatment of pHPT 
is parathyroidectomy.
Case report
A 33-year-old woman was admitted to the gynaecologi-
cal unit in the 14th week of her second pregnancy be-
cause of progressive weakness, severe abdominal pain, 
nausea, and vomiting. Her previous pregnancy ended 
in spontaneous miscarriage in the 10th week, in 2010. 
Medications used prior to hospitalisation included non-
steroid anti-inflammatory drugs (NSAID). The patient 
was seen for the first time in hospital in the 12th week 
of gestation with a diagnosis of acute kidney disease, 
probably due to NSAID and secondary hypertension. 
On admission to the gynaecological unit the patient 
suffered from severe central abdominal pain radiating 
to her back. On physical examination dehydration, 
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tachypnoea, tachycardia, and distended abdomen 
were found. Initial abnormal laboratory results ob-
tained within 24 hours are presented in Table I. Alanine 
aminotransferase, aspartate aminotransferase, total 
bilirubin, total protein, magnesium, sodium, potas-
sium, chlorides, international normalised ratio (INR), 
lipids, and thyroid autoantibodies were within normal 
ranges. An ultrasound indicated that the patient had 
oedematous pancreatitis, ascites, trace amount of right 
pleural exudate, kidney — hyperechogenic cortex, and 
medulla layers. A neck ultrasound showed that the 
thyroid gland was not enlarged and was normoecho-
genic, but below the left lobe a hypoechogenic tumour 
of size 33 × 13 × 21 mm was found (Fig. 1). An obstetric 
ultrasound indicated a single pregnancy alive, with 
a biparietal diameter (BPD) of 30.43 mm and a femur 
length (FL) of 15.6 mm. 
The treatment began with fasting, analgesia, intra-
venous fluids, antibiotics (clindamycin, metronidazole), 
dalteparin, hypotensive drugs (methyldopa, labetalol), 
furosemide, parenteral thiamazolum, and parenteral 
nutrition. 
Acute pancreatitis (Apache II score 16), hypercal-
caemic crisis in the course of pHPT, and thyrotoxicosis 
with impending storm (point scale for the diagnosis 
of thyroid storm — score 30) in the course of Graves’ 
disease (GD), and acute kidney disease were diagnosed. 
The patient was transferred on the following day to an 
Intensive Care Unit (ICU).
On ICU admission the patient was conscious, an-
xious with malaise and tremor, face and palms flush-
ing, abdominal pain, pruritus, borderline respiratory 
status with tachypnoea of 35 breaths per minute, blood 
pressure 165/100 mm Hg, tachycardia 135/min, renal 
dysfunction, hypercalcaemia (total calcium 17 mg/dL, 
ionized calcium 2,275 mmol/L), normothermia, with 
clinical severity status scored at 13 points according to 
the APACHE II score, and 41 points in SAPS 3 score. 
Treatment had been continued with continuous epi-
dural analgesia (0.125% bupivacaine with fentanyl, 
pruritus disappeared after fentanyl dose reduction), 
thiamazole, hydration and furosemide under strict 
monitoring of haemodynamic parameters, treatment 
with propranolol, hydrocortisone, and total parenteral 
nutrition was introduced. Continuous veno-venous 
haemodialysis (CVVHD) with citrate anticoagulation 
due to concerns about extradural catheter was started 
for elimination of excess calcium and for renal dysfunc-
tion, with a target calcium level below total 9.5 mg/dL 
recommended for foetal safety. Improvement in clinical 
status and laboratory parameters was achieved with 
good control of pain and anxiety, blood pressure and 
heart rhythm, calcium level (symptoms of tetany in 
the form of paraesthesia at the upper normal levels 
of calcium were observed), thyroid hormones and 
renal parameters, pancreatic markers, and nutritional 
status. The patient became tranquil with significant 
improvement in mood, respiratory parameters and 
comfort, disappearance of pain, tremor and flushing, 
normotension, and heart rate within normal limits. 
Parenteral nutrition was changed to enteral nutrition 
within three days. In control abdominal ultrasound 
pancreatic oedema as well as abdominal and pleural 
effusions disappeared, and the foetus was alive. An 
increase in calcium level from the target level up to 
13 mg/dL was observed between CVVHD sessions, re-
gardless of adequate hydration and furosemide therapy. 
After appropriate preparation for surgery, total thy-
roidectomy and a single parathyroid adenoma excision 
were performed on the 9th ICU day. Intraoperatively, 
a decrease of PTH concentration from 2302 to 50.5 pg/mL 
was observed. Histological examination of the removed 
tissue confirmed the presence of a benign adenoma 
of the parathyroid gland. After surgery the patient 
Table I. Laboratory evaluation on admission
Tabela I. Ocena laboratoryjna przy przyjęciu
Patient’s  
results
Normal ranges
White blood cells [10˘3/uL] 31.75 4.1–10.9
Creatinine [mg/dL] 1.9 0.7–1.2
eGFR (MDRD) 32 90–140
Urea [mg/dL] 61 10–50
Total serum calcium [mg/dL] 17.5 8.6–10.2
Albumin [g/L] 25.8 4–48
Phosphates [mg/dL] 5.3 2.7–4.5
Parathormone [pg/mL] 559.9 15.0–6  5.0
Lipase [U/L] 2219 13–60
Alfa-amylase [U/L] 2599 28–100
Urine amylase [U/L] 9114 ≤ 460
TSH [uIU/mL] 0.01 0.27–4.2
fT4 [pmol/L] 51.3 11.8–24.6
TSH-receptor antibodies [U/L] 1.84 < 1.0
CRP [mg/dL] 3.56 0–0.5
D-dimer [ng/mL] > 20 0–0.5
Glucose [mg/dL] 135 60–99
pH 7.24 7.35–7.45
HCO3 [mmol/L] 14.3 22–26
BE [mmol/L] –13.1 –3÷3
pO2 [mm Hg] 69.8 80–100
Urine Protein 58 mg/dL Protein neg
Glucose  
300 mg/dL
Glucose neg
Urine centrifuged > 100 WBC/HPF Up to 5WBC/HPF
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was extubated, the last session of CVVHD introduced 
and thiamazole discontinued, L-thyroxin started, and 
hydrocortisone gradually discontinued. The patient 
was transferred to the Department of Endocrinology 
on the 11th ICU day in good clinical condition. During 
the postoperative period hypocalcaemia requiring sup-
plementation was observed (hungry bone syndrome). 
In addition, vitamin D deficiency was diagnosed and 
cholecalciferol was introduced. Gestational diabetes 
was recognised in the 17th week of pregnancy. Because 
of insufficient glucose control during diet regimen, 
insulin treatment was introduced. Antihypertensive 
therapy was not necessary.
The patient was admitted to the gynaecological 
unit in the 27th week of gestation because of suspicion 
of intrauterine growth retardation (IUGR). On admis-
sion, her blood pressure was above 140/90 mm Hg, 
laboratory results indicated calcium levels at 8.4 mg/dL, 
phosphates at 2.4 mg/dL, PTH at 91.52 pg/mL, pro-
teinuria at 228 mg/day, haemoglobin at 10.6 g/dL and 
HbA1c at 5.1%. Treatment with calcium carbonate, 
cholecalciferol, L-thyroxin, ferrous chloride, dalteparin, 
and insulin were continued. Antihypertensive therapy 
was reintroduced. An obstetric ultrasound showed FL 
< 3rd percentile, the abdominal circumference (AC) at 
3rd percentile, BPD at the 80th percentile, and the head 
circumference (HC) at the 23rd percentile. The next 
hospitalisation started in the 34th week of gestation. 
A gestational ultrasound found that AC, FL, BPD, and 
HC were < 3rd percentile. Laboratory parameters were 
stable. In the 36th week, because of the absent end-dias-
tolic flow in the umbilical artery and low cerebro-pla-
cental ratio of 0.39, gestation was ended with caesarean 
section. A live-born infant, a male weighing 1600 g (< 
10th percentile) was born with Apgar score of 8. Signs of 
respiratory insufficiency were noted on physical exami-
nation requiring continuous positive airway pressure 
for three hours. The total serum calcium concentration 
was within normal limits. Hypoglycaemia, needing 
intra-venous glucose infusion, was observed during 
the first hour after delivery. From the 2nd neonatal day 
the baby’s general condition was stable. The newborn 
was breastfed. During ultrasound of heart and central 
nervous system no abnormalities were observed. 
On the 17th day of the puerperium the patient was 
discharged from the hospital with the baby (whose 
body weight had increased to 2180 g). Treatment with 
calcium carbonate, cholecalciferol, L-thyroxin, and 
dalteparin were continued. Insulin treatment was dis-
continued after the delivery.
Discussion
Calcium homeostasis is a very stable mechanism. PTH 
is one of the principal factors in the prevention of 
hypocalcaemia. The haemodilution observed during 
pregnancy results in the fall of serum albumin. As a 
result, the total serum calcium falls while the ionised 
Figure 1. The neck ultrasound — below the left lobe a hypoechogenic tumour of size 33 × 13 × 21 mm
Rycina 1. USG szyi — pod lewym płatem guz hipoechogeniczny o wymiarach 33 × 13 × 21 mm
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calcium remains constant during pregnancy. The physi-
ological changes associated with pregnancy, such as the 
active transport of blood from mother to foetus and 
increased urine calcium excretion in pregnant women, 
also affect the total calcium serum concentration. The 
normal ranges of calcium concentration for pregnant 
women are lower compared with the total population. 
Undiagnosed cases of pHPT may be connected with 
these pregnancy related changes. Complications asso-
ciated with pHPT in pregnancy have been reported to 
occur in up to 67% of mothers and in 80% of foetuses. 
Maternal complications include nephrolithiasis, bone 
disease, pancreatitis, mental status changes, and hy-
percalcaemic crisis [1]. The mother is especially at risk 
of hypercalcaemic crisis after delivery, when no treat-
ment is provided. There are also reported complications 
specific to pregnancy — hyperemesis gravidarum and 
preeclampsia [2, 5, 6]. Hypercalcaemic crisis is a very rare 
condition occurring during pregnancy. Only a few cases 
have been reported [7]. Other clinical findings, such as 
maternal hypertension, were also noted; however, this 
association remains inconclusive. Acute pancreatitis in 
pregnancy is a rare condition and pHPT is a potential 
aetiological factor.
Maternal and foetal complications, however, cannot 
be predicted based on duration or severity of hypercal-
caemia. In pHPT during pregnancy active transport of 
calcium ions from mother to foetus leads to suppres-
sion of the foetal parathyroid glands. After delivery the 
mother may suffer from worsening hypercalcaemia or 
even hypercalcaemic crisis since the active transport 
of calcium from mother to foetus is disrupted, but 
this life-threatening condition may occur also during 
pregnancy. On the other hand, a newborn may develop 
hypocalcaemic tetany [2, 3].
In the patient described in this case, hypercalcaemic 
crisis caused by pHPT coexisted with life-threatening 
thyrotoxicosis, acute pancreatitis, and hypertension. 
Life-threatening thyrotoxicosis or thyroid storm is a rare 
disorder characterised by a high mortality rate if not 
immediately recognised and treated aggressively. In our 
patient without previous history of GD thyrotoxicosis, 
the impending thyroid storm was probably connected 
with severe acute pancreatitis and hypercalcaemic cri-
sis. Gestational diabetes, which was later recognised, 
also influenced foetal growth.
The evaluation of appropriate foetal growth and the 
diagnosis of its disorders are essential elements in the 
care of pregnant women. Reported foetal complications 
include intrauterine growth retardation, low birth weight, 
premature birth, intrauterine foetal demise, postpartum 
neonatal tetany, and permanent hypoparathyroidism 
[2, 7]. A pregnancy complicated by intrauterine growth 
restriction is a pregnancy of high risk. We observed that 
hypertension and gestational diabetes also influenced the 
neonatal growth in our patient. 
The correct diagnosis of primary hyperparathy-
roidism in pregnancy is essential. Primary hyperpar-
athyroidism is diagnosed when PTH is elevated in the 
context of hypercalcaemia. Sometimes serum calcium 
levels fluctuate into the upper normal range and their 
repeated measurements are necessary. In patients with 
subtle pHPT, intermittent hypercalcaemia may occur. 
In patients with pHPT, low or low-normal serum phos-
phorus is noticed. Elevated or even upper-normal levels 
of the intact PTH level in the case of hypercalcaemia 
confirm hyperparathyroidism or one of its variants 
(familial benign hypocalciuric hypercalcaemia). The 
physiological changes observed in pregnancy should 
also be taken into consideration.
The use of preoperative localisation techniques in 
pregnant women is limited. Ultrasound plays the basic 
diagnostic role. Technetium-99m sestamibi scanning 
was also reported in cases with ectopic localisations 
of parathyroid adenoma [8]. Intra-operative PTH hor-
mone monitoring is also a helpful diagnostic method.
Treatment of hypercalcaemia in pregnant woman 
is not different from that in non-pregnant women. 
Dehydration should be corrected by intravenous fluid 
administration. Loop diuretics are administrated to 
promote calcium diuresis. In the case of hypercalcaemic 
crisis, the patient requires intensive treatment. The ap-
plication of bisphosphate is contraindicated in pregnant 
women (category C); however, it can be used after 
delivery. Calcitonin, because of its limited effect due to 
tachyphylaxis and category C, was not utilised [3, 6]. 
There have been a few cases where cinacalcet was ad-
ministrated during pregnancy or postpartum. If diuresis 
does not give satisfactory results by lowering the serum 
calcium, dialysis should be performed [3]. Diagnostic 
testing should be conducted in parallel with calcium 
lowering treatment. The only definitive treatment of 
pHPT is parathyroidectomy [8]. There is general agree-
ment that parathyroidectomy should be performed in 
pregnant women during the second trimester. In the 
case of symptomatic hypercalcaemia, surgical treatment 
can also be performed by an experienced surgeon even 
in the third trimester of pregnancy [1, 7]. 
Conclusions
In conclusion, clinical evidence of symptoms, signs, 
diagnosis, and treatment of pHPT in pregnancy is lim-
ited. The severity of the disease is classified by calcium 
levels. Additional conditions, as well as gestational 
age, also influence the choice of treatment. The above-
described pregnant patient with hypercalcaemic crisis 
and acute pancreatitis caused by pHPT with coexisting 
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hyperthyreosis underwent successful surgical treat-
ment in the 15th week of pregnancy. In the 36th week the 
gestation was ended by caesarean section. The live-born 
infant did not present abnormal calcium levels. 
The key factor for further reduction of maternal 
and foetal mortality is early awareness and recogni-
tion of the potential presence of a pHPT in a pregnant 
patient with history of miscarriage and clinical signs of 
hypercalcaemia.
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